AT279430T - Process for improving the serum half-life of biologically active molecules - Google Patents

Process for improving the serum half-life of biologically active molecules

Info

Publication number
AT279430T
AT279430T AT99912297T AT99912297T AT279430T AT 279430 T AT279430 T AT 279430T AT 99912297 T AT99912297 T AT 99912297T AT 99912297 T AT99912297 T AT 99912297T AT 279430 T AT279430 T AT 279430T
Authority
AT
Austria
Prior art keywords
improving
life
process
biologically active
serum half
Prior art date
Application number
AT99912297T
Other languages
German (de)
Inventor
Robert J Drummond
Steve Rosenberg
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US7696498P priority Critical
Application filed by Chiron Corp filed Critical Chiron Corp
Priority to PCT/US1999/004899 priority patent/WO1999045026A1/en
Publication of AT279430T publication Critical patent/AT279430T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49Urokinase; Tissue plasminogen activator
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6456Plasminogen activators
    • C12N9/6462Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21073Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
AT99912297T 1998-03-05 1999-03-05 Process for improving the serum half-life of biologically active molecules AT279430T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US7696498P true 1998-03-05 1998-03-05
PCT/US1999/004899 WO1999045026A1 (en) 1998-03-05 1999-03-05 Method for increasing the serum half-life of a biologically active molecule

Publications (1)

Publication Number Publication Date
AT279430T true AT279430T (en) 2004-10-15

Family

ID=22135286

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99912297T AT279430T (en) 1998-03-05 1999-03-05 Process for improving the serum half-life of biologically active molecules

Country Status (6)

Country Link
US (4) US6423685B1 (en)
EP (1) EP1062230B1 (en)
JP (1) JP2002505338A (en)
AT (1) AT279430T (en)
DE (1) DE69921102T2 (en)
WO (1) WO1999045026A1 (en)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT279430T (en) * 1998-03-05 2004-10-15 Chiron Corp Process for improving the serum half-life of biologically active molecules
US6887674B1 (en) * 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
SI1783222T1 (en) 1998-10-23 2012-09-28 Kirin Amgen Inc Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity.
AU9272401A (en) * 2000-09-18 2002-03-26 Biogen Inc Cripto mutant and uses thereof
PE20020376A1 (en) * 2000-09-29 2002-05-13 Abbott Lab Antiangiogenic polypeptides and methods for inhibiting angiogenesis
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
EP1837031B1 (en) * 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
AT413031B (en) * 2002-08-06 2005-10-15 Stockinger Hannes Dr Use of cd222 or derived peptide to inhibit fibrinolysis, cell adhesion and cell migration in vitro
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040229810A1 (en) * 2002-10-22 2004-11-18 Antonio Cruz Gastrin compositions and formulations, and methods of use and preparation
WO2004060299A2 (en) 2002-12-26 2004-07-22 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
BR0317752A (en) * 2002-12-26 2005-11-22 Mountain View Pharmaceuticals Polymeric cytokine conjugates, chemokines, growth factors, polypeptide hormones and their antagonists with conserved receptor binding activity
US7662915B2 (en) * 2003-01-18 2010-02-16 Pegsphere Co., Ltd. Peptides having protected amines of untargeted sites, methods for production thereof and of specifically conjugated PEG peptides using the same
EP2275445A3 (en) * 2004-03-12 2012-02-29 Vasgene Therapeutics, Inc. Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
KR20070034465A (en) 2004-03-12 2007-03-28 바스진 테라퓨틱스, 인크. Polypeptide compounds to inhibit angiogenesis and tumor growth
US7381410B2 (en) * 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
US7585967B2 (en) * 2003-03-12 2009-09-08 Vasgene Therapeutics, Inc. Nucleic acid compounds for inhibiting angiogenesis and tumor growth
ES2340494T3 (en) 2003-04-15 2010-06-04 Glaxosmithkline Llc Mutants of replacement of human il-18 and its conjugates.
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
US20050131028A1 (en) * 2003-09-11 2005-06-16 Pharmacia Corporation Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
US20060228331A1 (en) * 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
EP2633866A3 (en) * 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
SG135176A1 (en) 2004-02-02 2007-09-28 Ambrx Inc Modified human four helical bundle polypeptides and their uses
EP1771205B1 (en) * 2004-06-18 2016-10-26 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
EP1773400A2 (en) * 2004-07-08 2007-04-18 Amgen Inc. Therapeutic peptides
MX2007000728A (en) * 2004-07-21 2007-03-15 Ambrx Inc Biosynthetic polypeptides utilizing non-naturally encoded amino acids.
ES2529451T3 (en) * 2004-09-23 2015-02-20 Vasgene Therapeutics, Inc. polypeptide compounds to inhibit angiogenesis and tumor growth
CN103690936A (en) 2004-12-22 2014-04-02 Ambrx公司 Modified human growth hormone
KR20070100299A (en) 2004-12-22 2007-10-10 암브룩스, 인코포레이티드 Methods for expression and purification of recombinant human growth hormone
US7332571B2 (en) 2004-12-22 2008-02-19 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
EP1833993A4 (en) 2004-12-22 2009-07-22 Ambrx Inc Formulations of human growth hormone comprising a non-naturally encoded amino acid
EP1836298B1 (en) 2004-12-22 2012-01-18 Ambrx, Inc. COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF
KR20080013878A (en) 2005-04-18 2008-02-13 노보 노르디스크 에이/에스 Il-21 variants
WO2006125201A2 (en) * 2005-05-19 2006-11-23 Centocor, Inc. Anti-biotin-pegylated-mcp-1 mutein antibodies, compositions, methods and uses
AU2006255122B2 (en) 2005-06-03 2010-10-21 Ambrx, Inc. Improved human interferon molecules and their uses
AU2006294873A1 (en) * 2005-09-23 2007-04-05 Vasgene Therapeutics, Inc. Use of EphrinB2 directed agents for the treatment or prevention of viral infections
CN101454461A (en) 2005-11-16 2009-06-10 Ambrx公司 Methods and compositions comprising non-natural amino acids
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
WO2008030558A2 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
CN101511856B (en) 2006-09-08 2016-01-20 Ambrx公司 In vertebrate cells, suppressor trna transcribes
CN101541955B (en) 2006-09-08 2016-09-28 Ambrx公司 Heterozygosis for vertebrate cells suppresses tRNA
CN101553501A (en) 2006-10-26 2009-10-07 诺沃-诺迪斯克有限公司 Il-21 variants
CA2671665A1 (en) * 2006-12-21 2008-06-26 Novo-Nordisk A/S Interleukin-21 variants with altered binding to the il-21 receptor
WO2008121563A2 (en) 2007-03-30 2008-10-09 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
MX2009011870A (en) 2007-05-02 2009-11-12 Ambrx Inc Modified interferon beta polypeptides and their uses.
EP2513137B1 (en) 2009-12-17 2018-02-28 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
MX2010005317A (en) 2007-11-20 2010-06-02 Ambrx Inc Modified insulin polypeptides and their uses.
EP2247743B1 (en) 2008-02-08 2016-04-06 Ambrx, Inc. Modified leptin polypeptides and their uses
MX2011000859A (en) 2008-07-23 2011-02-24 Ambrx Inc Modified bovine g-csf polypeptides and their uses.
US9121024B2 (en) 2008-09-26 2015-09-01 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
JP5694171B2 (en) 2008-09-26 2015-04-01 アンブルックス,インコーポレイテッドAmbrx,Inc. Modified animal erythropoietin polypeptides and their use
US9052304B2 (en) 2009-03-13 2015-06-09 Terrasep, Llc Methods and apparatus for centrifugal liquid chromatography
EP2416797A4 (en) 2009-04-10 2013-04-24 Amylin Pharmaceuticals Llc Amylin agonist compounds for estrogen-deficient mammals
WO2010129248A1 (en) 2009-05-06 2010-11-11 Centocor Ortho Biotech Inc. Melanocortin receptor binding conjugates
RU2012126101A (en) 2009-11-23 2013-12-27 АМИЛИН ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи,США Polyepeptide conjugate
WO2011087810A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
CA2788021A1 (en) 2010-01-27 2011-08-04 Children's Medical Center Corporation Pro-angiogenic fragments of prominin-1 and uses thereof
MX346786B (en) 2010-08-17 2017-03-31 Ambrx Inc Modified relaxin polypeptides and their uses.
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
SG195183A1 (en) 2011-05-27 2013-12-30 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
KR20190115109A (en) 2011-05-27 2019-10-10 암브룩스, 인코포레이티드 Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
EP2793921B1 (en) 2011-12-22 2019-04-24 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
US9611305B2 (en) 2012-01-06 2017-04-04 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
US20150152190A1 (en) 2012-06-07 2015-06-04 Ambrx, Inc. Prostate-Specific Membrane Antigen Antibody Drug Conjugates
CN104583235B (en) 2012-06-08 2019-03-01 苏特罗生物制药公司 The antibody of the Unnatural amino acid residues containing site-specific, its preparation and application
CN104619350A (en) 2012-06-14 2015-05-13 Ambrx公司 Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
WO2013192360A1 (en) 2012-06-19 2013-12-27 Ambrx, Inc. Anti-cd70 antibody drug conjugates
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc Modified fc proteins, including location-specific non-natural amino acid residues, conjugates thereof, methods of producing its and procedures for use thereof
US9764039B2 (en) 2013-07-10 2017-09-19 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
SG11201702824UA (en) 2014-10-24 2017-05-30 Squibb Bristol Myers Co Modified fgf-21 polypeptides and uses thereof
CN109069664A (en) 2016-01-27 2018-12-21 苏特罗生物制药公司 Anti- CD74 antibody coupling matter, the application method of the composition comprising anti-CD74 antibody coupling matter and anti-CD74 antibody coupling matter
WO2018148419A1 (en) 2017-02-08 2018-08-16 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
WO2019023316A1 (en) 2017-07-26 2019-01-31 Sutro Biopharma, Inc. Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
WO2019055909A1 (en) 2017-09-18 2019-03-21 Sutro Biopharma, Inc. Anti-folate receptor alpha antibody conjugates and their uses

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
JPH04218000A (en) 1990-02-13 1992-08-07 Kirin Amgen Inc Modified polypeptide
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5362852A (en) 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
NZ244778A (en) 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
WO1994006151A1 (en) 1992-09-08 1994-03-17 Kabushiki Kaisha Komatsu Seisakusho Method of detecting end point of etching
BR9307092A (en) 1992-09-24 1999-03-30 Chiron Corp A process for synthesizing monomer N-substituted polyamide oligomer mixture of at least two different oligomers poly (N-substituted glycine) treatment process antisense method of synthesizing compound composition polyamide compound and process for preparing mixture of amide compounds
GB9225448D0 (en) * 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
DE69432608T2 (en) * 1993-06-01 2004-02-26 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Expression of inhibitors of urokinase-
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
AT279430T (en) * 1998-03-05 2004-10-15 Chiron Corp Process for improving the serum half-life of biologically active molecules

Also Published As

Publication number Publication date
DE69921102D1 (en) 2004-11-18
US20020182705A1 (en) 2002-12-05
DE69921102T2 (en) 2006-02-02
EP1062230A1 (en) 2000-12-27
EP1062230B1 (en) 2004-10-13
US20070135349A1 (en) 2007-06-14
US20070060513A9 (en) 2007-03-15
US20050197297A1 (en) 2005-09-08
WO1999045026A1 (en) 1999-09-10
US6423685B1 (en) 2002-07-23
US20020086819A1 (en) 2002-07-04
US7022673B2 (en) 2006-04-04
JP2002505338A (en) 2002-02-19

Similar Documents

Publication Publication Date Title
DE69632834D1 (en) A process for the stabilization of liquid sludge
AT220603T (en) Two-stage process for dewatering of plastic dispersions
DE69528712D1 (en) System for execution of kardiakverfahren
DE69914773D1 (en) A process for the purification of 1,3-propanediol
DE69422687T2 (en) Biosensor for hematocrit
DE69528057D1 (en) Tocopherolzusammensetzungen for delivery of biologically active substances
AT164085T (en) A process for the electrodeposition of hydroxyapatitschichten
DE69603810D1 (en) A process for the preparation of nitriles
DE69901937T2 (en) A process for the production of electrodes
DE69816815D1 (en) A process for the purification of lactic acid
DE1020534T1 (en) A process for the synthesis of nucleic acid
DE69911248D1 (en) Improved process for alkylation of aromatics
DE69516523T2 (en) A process for the recovery of polyhydroxyalkanoic acid
DE856937T1 (en) System for determining the commutation process and
DE69910557D1 (en) A process for the purification of aminonitrile
DE69627613D1 (en) Process for the recovery of substrates
DE69626392D1 (en) Stable reagents for the production of radio-pharmaceuticals
DE69604147T2 (en) Liquid zuzammensetzung for stabilization of amino acid-herbicidal
DE68901960D1 (en) Process for the catalytic cleavage of kohlenwasserstoffeinsaetzen.
DE69434066D1 (en) A process for the immobilization of nucleic acid molecules
DE69721289D1 (en) A process for the purification of proteins rekombinanaten
DE69515352T2 (en) An integrated process for production of Mitteldistillaten
AT248911T (en) Magnetic particles for washing nucleic acids
AT269369T (en) Combined process for the production of cascade polymer surfaces
AT231830T (en) alpha-olefins process for the preparation of

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties